Treatment decisions should reflect patient preferences, comorbidities, and risk factors
Fasting plasma glucose and incidence of diabetes implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA Cohort study
Atamer Y, Kocyigit Y, Yokus B, et al
Weight loss plateaus on GLP-1 receptor agonists affect roughly 40% of patients by month six of therapy
showed that individual with above-median serum MSTN concentrations had higher brachial diastolic blood pressure and higher carotid - femoral pulse velocity compared to controls ( 4.4 MSTN-mediated tissue crosstalk in diseases The expression of MSTN is not limited to skeletal muscle, it is also expressed in myocardium, adipose tissue, brain, kidney and circulating white blood cells ( 5 The inhibitor of MSTN In view of the importance of MSTN in regulating muscle homeostasis, the inhibitors targeting the MSTN signaling pathway have been developed for clinical use to improve patients with sarcopenia and muscular dystrophy
